CTOs on the Move

Hospital Physician Partners

www.hppartners.com

 
As one of the largest and fastest-growing Emergency and Hospital Medicine groups in the nation, we partner with more than 5,000 world-class providers who treat more than 6 million patients annually. Physician-led, our team consists of motivated, personable, highly qualified people interested in putting the patient first. We’re committed to doing the right thing for the patients, physicians, and hospitals we serve. Which is why 98% of our physicians recommend us to colleagues and friends. William C. Schumacher, M.D., a board certified emergency medicine physician, formally founded the Schumacher Group in 1994. The philosophy behind Schumacher Group`s founding was based ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

WellDoc

WellDoc is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MEDNET USA

MEDNET USA is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MMR Information Systems

MMRGlobal, Inc., formerly known as MMR Information Systems, Inc., provides secure, easy-to-use multilingual Personal Health Records (PHRs) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, professional organizations and affinity groups.

Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.

Suveto

Our vision is for all veterinary professionals to be empowered and equipped to take ownership of their professional growth, personal well-being and veterinary medicine.